Sclerotherapy is a safe method of treatment of chronic venous disorders in older patients: A prospective and comparative study of consecutive patients

Abstract

Objectives

An aging population requires evaluation of methods of treatment for older patients. Our objective was to evaluate the indications, practical modalities, safety and tolerability of sclerotherapy in patients 75 years of age and older (group 1) and compare with a control group of patients 18 to74 years of age (group 2).

Method

This observational, multicentre, prospective and comparative study was conducted by the French Society of Phlebology. Each centre collected in 10 to 20 patients ≥75 years of age and an equal number of patients <75 years of age treated by sclerotherapy, the treatment indication, the patient's personal history, the CEAP clinical class, the type of the veins being treated, the characteristics of sclerotherapy and the complications (immediately after treatment and at one-month follow-up).

Results

Population: In total, 418 patients were enrolled in 15 centres: 176 patients in group 1 (mean: 79.4 years) and 242 patients in group 2 (mean: 52.7 years).CEAP clinical classes C4, C5 and C6, history of deep vein thrombosis (12.5%) and superficial vein thrombosis (11.9%), long-term anticoagulant therapy (9.1%) and antiplatelet therapy (16.5%) were more frequent in older patients.All types of veins were treated from saphenous veins to telangiectasias.

Sclerotherapy features: There was no difference in concentration of the sclerosing agents. When foam sclerotherapy was used (84% of patients), the injected volume was lower in group 1. Complications: One vasovagal syncope occurred in group 1. One asymptomatic distal deep vein thrombosis, confined to the Medial Gastrocnemius Veins, was reported in both groups at one-month follow-up.

Conclusions

This study shows the feasibility and safety of sclerotherapy in older patients, with no specific complications nor need for special precautions.

Keywords

Foam sclerotherapy sclerotherapy echo-sclerotherapy varicose veins older patients

Get full access to this article

View all access options for this article.

References

Rabe

Otto

Schliephake

. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Endovasc Vasc Surg 2008; 35: 238–245.

Hamel-Desnos

Guias

Desnos

. Foam sclerotherapy of the saphenous veins. Randomised controlled trial with or without compression. Eur J Vasc Endovasc Surg 2010; 39: 500–507.

Gillet

. Foam sclerotherapy of saphenous veins – Results and side effects. Rev Vasc Med 2013; 1: 24–29.

Coleridge

. Chronic venous disease treated by ultrasound guided foam sclerotherapy. Eur J Vasc Endovasc Surg 2006; 32: 577–583.

Bradbury

Bate

Pang

. Ultrasound-guided foam sclerotherapy is a safe and clinically effective treatment for superficial venous reflux. J Vasc Surg 2010; 52: 939–945.

Rasmussen

Lawaetz

Serup

. Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins with 3-years follow-up. J Vasc Surg 2013; 1: 349–356.

Darvall

Bate

Adam

. Duplex ultrasound outcomes following ultrasound-guided foam sclerotherapy of symptomatic primary great saphenous varicose veins. Eur J Vasc Endovasc Surg 2010; 40: 534–539.

Chapman-Smith

Browne

. Prospective five year study of ultrasound guided foam sclerotherapy in the treatment of great saphenous vein reflux. Phlebology 2009; 24: 183–188.

Shadid

Ceulen

Nelemans

. Randomized clinical trial of ultrasound-guided foam sclerotherapy versus surgery for the incompetent great saphenous vein. Br J Surg 2012; 99: 1062–1070.

10.

Gillet

Lausecker

Sica

. Is the treatment of the small saphenous veins with foam sclerotherapy at risk of deep vein thrombosis? Phlebology 2014; 29: 600–607.

11.

Eklöf

Rutherford

Bergan

. American venous forum international Ad Hoc committee for revision of the CEAP classification. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 2004; 40: 1248–1252.

12.

Cavezzi

Tessari

. Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology 2009; 24: 247–251.

13.

Gillet

. Neurological complications of foam sclerotherapy: fears and reality. Phlebology 2011; 26: 277–279.

14.

Cavezzi

Parsi

. Complications of foam sclerotherapy. Phlebology 2012; 27 (Suppl 1): 46–51.

15.

Sarvananthan

Shepherd

Willenberg

. Neurological complications of sclerotherapy for varicose veins. J Vasc Surg 2012; 55: 243–251.

16.

Gillet

Donnet

Lausecker

. Pathophysiology of visual disturbances occurring after foam sclerotherapy. Phlebology 2010; 25: 261–266.

17.

Rabe

Breu

Cavezzi

. European guidelines for sclerotherapy in chronic venous disorders. Phlebology 2014; 29: 338–354.

18.

Gillet

Guedes

Guex

. Side effects and complications of foam sclerotherapy of the great and small saphenous veins: a controlled multicentre prospective study including 1025 patients. Phlebology 2009; 34: 131–138.

19.

Guex

Allaert

Gillet

. Immediate and mid-term complications of sclerotherapy. Report of a prospective multi-centric registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005; 31: 123–128.

20.

Hamel-Desnos

Desnos

Allaert . Thermal ablation of saphenous veins is feasible and safe in patients older than 75 years: a prospective study (EVTA study). Phlebology 2015; 30: 525–532.